Article Abstract

Validation of a serum 4-microRNA signature for the detection of lung cancer

Authors: Xia Yang, Wenmei Su, Xiuyuan Chen, Qianqian Geng, Jingyi Zhai, Hu Shan, Chunfang Guo, Zhuwen Wang, Han Fu, Hui Jiang, Jules Lin, Kiran Hari Lagisetty, Jie Zhang, Yali Li, Shuanying Yang, Pierre P. Massion, David G. Beer, Andrew C. Chang, Nithya Ramnath, Guoan Chen


Background: Our previous studies have identified a serum-based 4-microRNA (4-miRNA) signature that may help distinguish patients with lung cancer (LC) from non-cancer controls (NCs). Here, we used an extended independent cohort of 398 subjects to further validate the diagnostic ability of this 4-miRNA signature.
Methods: Using quantitative reverse transcription polymerase chain reaction (qRT-PCR), expression of the 4-miRNAs was assessed in a total of 398 sera that included 213 LC patients and 185 NCs. A logistic regression model using training-test sets, receiver operating characteristic (ROC) curve analysis and t-test were used to test the impact of varying expression of these miRNAs on its diagnostic accuracy for LC. The cell proliferation and colony formation affected by these miRNAs, as well as gene ontology (GO) analysis of miRNA target genes were performed.
Results: The levels of the 4-miRNAs were significantly higher in the serum of patients with LCs as compared to NCs. Using a logistic regression prediction model based on training and test sets analysis, we obtained the area under the curve (AUC) of 0.921 [95% confidence interval (CI), 0.876–0.966] on the test set with specificity 90.6%, sensitivity 77.9%, accuracy 84.1%, positive predictive value (PPV) 89.8% and negative predictive value (NPV) 79.5%.
Conclusions: We have verified that this serum 4-miRNA signature could provide a promising noninvasive biomarker for the prediction of LC, particularly in patients with indeterminate lung nodules on screening CT scans.